BPTES

• CAT Number: I003115
• CAS Number: 314045-39-1
• Molecular Formula: C24H24N6O2S3
• Molecular Weight: 524.71
• Purity: ≥95%
• Synonyms: N,N/’-[thiobis(2,1-ethanediyl-1,3,4-thiadiazole-5,2-diyl)]bis-benzeneacetamide
• Target: Glutaminase
• Solubility: 10 mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 2-phenyl-N-[5-[2-[2-[5-[(2-phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]ethylsulfanyl]ethyl]-1,3,4-thiadiazol-2-yl]acetamide
• InChI: InChI=1S/C24H24N6O2S3/c31-19(15-17-7-3-1-4-8-17)25-23-29-27-21(34-23)11-13-33-14-12-22-28-30-24(35-22)26-20(32)16-18-9-5-2-6-10-18/h1-10H,11-16H2,(H,25,29,31)(H,26,30,32)
• InChIKey: MDJIPXYRSZHCFS-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)CC(=O)NC2=NN=C(S2)CCSCCC3=NN=C(S3)NC(=O)CC4=CC=CC=C4

BPTES(CAT: I003115) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS), an enzyme critical for converting glutamine to glutamate in cellular metabolism. By inhibiting GLS, BPTES disrupts glutamine metabolism, reducing the availability of glutamate for bioenergetics and biosynthesis, processes often upregulated in cancer cells. It has been widely used as a molecular probe to investigate the therapeutic potential of GLS inhibition in cancer research and metabolic studies. BPTES provides valuable insights into the role of glutamine metabolism in tumor growth and supports the development of GLS-targeted therapies for cancers and metabolic disorders dependent on glutamine.